The New England journal of medicine, 2022-06, Vol.386 (22), p.2084-2096
- Hager, Karen J.
- Pérez Marc, Gonzalo
- Gobeil, Philipe
- Diaz, Ricardo S.
- Heizer, Gretchen
- Llapur, Conrado
- Makarkov, Alexander I.
- Vasconcellos, Eduardo
- Pillet, Stéphane
- Riera, Fernando
- Saxena, Pooja
- Geller Wolff, Priscila
- Bhutada, Kapil
- Wallace, Garry
- Aazami, Hessam
- Jones, Christine E.
- Polack, Fernando P.
- Ferrara, Luciana
- Atkins, Judith
- Boulay, Iohann
- Dhaliwall, Jiwanjeet
- Charland, Nathalie
- Couture, Manon M.J.
- Jiang-Wright, Julia
- Landry, Nathalie
- Lapointe, Sophie
- Lorin, Aurélien
- Mahmood, Asif
- Moulton, Lawrence H.
- Pahmer, Emmy
- Parent, Julie
- Séguin, Annie
- Tran, Luan
- Breuer, Thomas
- Ceregido, Maria-Angeles
- Koutsoukos, Marguerite
- Roman, François
- Namba, Junya
- D’Aoust, Marc-André
- Trepanier, Sonia
- Kimura, Yosuke
- Ward, Brian J.
2022
Details
- Autor(en) / Beteiligte
- Hager, Karen J.
- Pérez Marc, Gonzalo
- Gobeil, Philipe
- Diaz, Ricardo S.
- Heizer, Gretchen
- Llapur, Conrado
- Makarkov, Alexander I.
- Vasconcellos, Eduardo
- Pillet, Stéphane
- Riera, Fernando
- Saxena, Pooja
- Geller Wolff, Priscila
- Bhutada, Kapil
- Wallace, Garry
- Aazami, Hessam
- Jones, Christine E.
- Polack, Fernando P.
- Ferrara, Luciana
- Atkins, Judith
- Boulay, Iohann
- Dhaliwall, Jiwanjeet
- Charland, Nathalie
- Couture, Manon M.J.
- Jiang-Wright, Julia
- Landry, Nathalie
- Lapointe, Sophie
- Lorin, Aurélien
- Mahmood, Asif
- Moulton, Lawrence H.
- Pahmer, Emmy
- Parent, Julie
- Séguin, Annie
- Tran, Luan
- Breuer, Thomas
- Ceregido, Maria-Angeles
- Koutsoukos, Marguerite
- Roman, François
- Namba, Junya
- D’Aoust, Marc-André
- Trepanier, Sonia
- Kimura, Yosuke
- Ward, Brian J.
- Titel
- Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine
- Ist Teil von
- The New England journal of medicine, 2022-06, Vol.386 (22), p.2084-2096
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- In this trial involving more than 24,000 participants, the efficacy of two doses of a viruslike-particle, plant-based vaccine with adjuvant was 69.5% against symptomatic Covid-19 and 78.8% against moderate-to-severe disease. More than 80% of vaccine recipients had local or systemic adverse effects, which were generally mild and short-lived.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2201300Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9127773
- Format
- –
- Schlagworte
- Adjuvants, Adjuvants, Immunologic - administration & dosage, Adjuvants, Immunologic - adverse effects, Adjuvants, Immunologic - therapeutic use, Adjuvants, Vaccine - administration & dosage, Adjuvants, Vaccine - adverse effects, Adjuvants, Vaccine - therapeutic use, Adult, Adverse events, Antibodies, Antibodies, Viral, Coronavirus, Coronaviruses, COVID-19 - genetics, COVID-19 - prevention & control, COVID-19 - virology, COVID-19 vaccines, COVID-19 Vaccines - administration & dosage, COVID-19 Vaccines - adverse effects, COVID-19 Vaccines - therapeutic use, Double-Blind Method, Glycoproteins, Humans, Immunological adjuvants, Infectious Disease, Injections, Intramuscular, Laboratories, Original, Pandemics, Placebos, Plant products, Population, SARS-CoV-2 - genetics, Severe acute respiratory syndrome coronavirus 2, Spike glycoprotein, Statistical analysis, Testing, Vaccination, Vaccine efficacy, Vaccines, Viral Infections